EXSPF yields 99.50% · JNJ yields 2.14%● Live data
📍 EXSPF pulled ahead of the other in Year 1
Combined, EXSPF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EXSPF + JNJ for your $10,000?
Expert.ai S.p.A., an artificial intelligence (AI) platform company, develops and sells cognitive computing software products based on AI algorithms to read and understand written language worldwide. The company offers expert.ai Platform that captures the strategic value of language data; expert.ai Answers, a customer support automation software that allows human like interaction between customers and internal staff, using the language of business and users; expert.ai Discover, a text analytics, and extraction and categorization software; expert.ai for Insurance that automate insurance claims management with natural language understanding; and expert.ai for Life Sciences to mimic the human like comprehension of scientific content, such as publications, patents, clinical trials, or medical reports. It serves the banking and insurance, public administration, life science and pharma, oil and gas, media and publishing, and telecom and utilities industries, as well as defense, and intelligence and law enforcement industries. Expert.ai S.p.A. has a strategic partnership agreement with WealthIntel Inc. to facilitate innovations in natural language and text analytics. The company was formerly known as Expert System S.p.A. and changed its name to Expert.ai S.p.A. in May 2021. Expert.ai S.p.A. was founded in 1989 and is headquartered in Modena, Italy.
Full EXSPF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.